BR112023024571A2 - Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos - Google Patents
Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmosInfo
- Publication number
- BR112023024571A2 BR112023024571A2 BR112023024571A BR112023024571A BR112023024571A2 BR 112023024571 A2 BR112023024571 A2 BR 112023024571A2 BR 112023024571 A BR112023024571 A BR 112023024571A BR 112023024571 A BR112023024571 A BR 112023024571A BR 112023024571 A2 BR112023024571 A2 BR 112023024571A2
- Authority
- BR
- Brazil
- Prior art keywords
- chk1
- inhibitors
- checkpoint kinase
- methods
- checkpoint
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193990P | 2021-05-27 | 2021-05-27 | |
| PCT/US2022/031141 WO2022251502A1 (en) | 2021-05-27 | 2022-05-26 | Checkpoint kinase 1 (chk1) inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024571A2 true BR112023024571A2 (pt) | 2024-02-06 |
Family
ID=84229213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024571A BR112023024571A2 (pt) | 2021-05-27 | 2022-05-26 | Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11707462B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4347582A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024520481A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240021188A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117715905A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022282384A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024571A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3219348A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308759A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014028A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202313588A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022251502A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023002453A2 (pt) | 2020-08-12 | 2023-05-02 | Boundless Bio Inc | Composições de agente de via de estresse de replicação e métodos para tratar câncer |
| MX2023006364A (es) * | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| EP4347582A4 (en) | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF |
| CA3241992A1 (en) * | 2021-12-24 | 2023-06-29 | Seiji Kamioka | 1h-pyrazole-3-amine derivative having bicyclic backbone |
| CN119546588A (zh) * | 2022-05-24 | 2025-02-28 | 无界生物公司 | 吡啶检查点激酶1(chk1)抑制剂及其用途 |
| CN119255990A (zh) * | 2022-05-25 | 2025-01-03 | 曙方医药 | 作为检查点激酶1抑制剂的含氮五元杂环衍生物及其用途 |
| EP4626433A1 (en) * | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| TW202440549A (zh) * | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶1(chk1)抑制劑及其用途 |
| EP4683635A1 (en) * | 2023-03-20 | 2026-01-28 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| JP2026513823A (ja) * | 2023-04-03 | 2026-05-01 | バウンドレス バイオ,インク. | チェックポイントキナーゼ1(chk1)阻害剤の結晶形態およびその使用 |
| US20260232659A1 (en) * | 2023-04-03 | 2026-08-13 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
| EP4753712A1 (en) * | 2023-08-02 | 2026-06-10 | Health Research, Inc. | Sequential treatment method for p53-deficient cancer |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026108769A1 (en) | 2024-11-19 | 2026-05-28 | Groovy Medicine (Hangzhou) Ltd. | Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof |
| WO2026108771A2 (en) | 2024-11-19 | 2026-05-28 | Groovy Medicine (Hangzhou) Ltd. | Substituted heteroaromatic compounds as inhibitors of checkpoint kinase 1 and notch signaling pathway and uses thereof |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
| CN122031724A (zh) * | 2026-04-17 | 2026-05-15 | 中国科学院杭州医学研究所 | 编码p16蛋白的mRNA在制备用于治疗胰腺癌的药物中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0110302A (pt) * | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
| US20050209297A1 (en) * | 2000-08-31 | 2005-09-22 | Pfizer Inc | Pyrazole derivatives |
| DZ3398A1 (fr) * | 2000-08-31 | 2002-03-07 | Pfizer Prod Inc | Derives pyrazole et leur utilisation comme inhibiteurs des proteines kinases |
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CA3013514C (en) * | 2016-02-04 | 2021-11-23 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| KR20220042159A (ko) * | 2019-08-01 | 2022-04-04 | 인테그랄 바이오사이언스 피브이티. 엘티디. | 키나제 억제제로서의 헤테로사이클릭 화합물 및 이의 용도 |
| CN112457306A (zh) * | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| CN111253370B (zh) | 2020-03-24 | 2021-08-03 | 浙江大学 | N-多取代吡啶-2-氨基嘧啶类衍生物及用途 |
| EP4741018A3 (en) * | 2020-06-19 | 2026-07-15 | Anaxis Pharma Pty Ltd | Sulphonamide compounds |
| BR112023002453A2 (pt) | 2020-08-12 | 2023-05-02 | Boundless Bio Inc | Composições de agente de via de estresse de replicação e métodos para tratar câncer |
| WO2022087326A1 (en) | 2020-10-23 | 2022-04-28 | Celgene Corporation | Heterocyclic compounds and their use for treatment of helminthic infections and diseases |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| MX2023006364A (es) * | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
| EP4347582A4 (en) | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF |
| CA3241992A1 (en) | 2021-12-24 | 2023-06-29 | Seiji Kamioka | 1h-pyrazole-3-amine derivative having bicyclic backbone |
| CN119546588A (zh) | 2022-05-24 | 2025-02-28 | 无界生物公司 | 吡啶检查点激酶1(chk1)抑制剂及其用途 |
| CN119255990A (zh) | 2022-05-25 | 2025-01-03 | 曙方医药 | 作为检查点激酶1抑制剂的含氮五元杂环衍生物及其用途 |
| JPWO2023229032A1 (cg-RX-API-DMAC7.html) | 2022-05-27 | 2023-11-30 | ||
| TW202440549A (zh) | 2022-11-29 | 2024-10-16 | 美商無界生物公司 | 檢查點激酶1(chk1)抑制劑及其用途 |
| EP4626433A1 (en) | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
| EP4683635A1 (en) | 2023-03-20 | 2026-01-28 | Boundless Bio, Inc. | Uses of a checkpoint kinase 1 (chk1) inhibitor |
| JP2026513823A (ja) | 2023-04-03 | 2026-05-01 | バウンドレス バイオ,インク. | チェックポイントキナーゼ1(chk1)阻害剤の結晶形態およびその使用 |
| US20260232659A1 (en) | 2023-04-03 | 2026-08-13 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitor pharmaceutical composition |
-
2022
- 2022-05-26 EP EP22812165.3A patent/EP4347582A4/en active Pending
- 2022-05-26 MX MX2023014028A patent/MX2023014028A/es unknown
- 2022-05-26 BR BR112023024571A patent/BR112023024571A2/pt unknown
- 2022-05-26 WO PCT/US2022/031141 patent/WO2022251502A1/en not_active Ceased
- 2022-05-26 TW TW111119737A patent/TW202313588A/zh unknown
- 2022-05-26 IL IL308759A patent/IL308759A/en unknown
- 2022-05-26 CA CA3219348A patent/CA3219348A1/en active Pending
- 2022-05-26 KR KR1020237044236A patent/KR20240021188A/ko active Pending
- 2022-05-26 CN CN202280052765.2A patent/CN117715905A/zh active Pending
- 2022-05-26 AU AU2022282384A patent/AU2022282384A1/en not_active Abandoned
- 2022-05-26 JP JP2023573047A patent/JP2024520481A/ja active Pending
- 2022-08-29 US US17/897,667 patent/US11707462B2/en active Active
-
2023
- 2023-06-01 US US18/327,775 patent/US12527790B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4347582A1 (en) | 2024-04-10 |
| AU2022282384A1 (en) | 2023-12-14 |
| MX2023014028A (es) | 2023-12-12 |
| KR20240021188A (ko) | 2024-02-16 |
| US12527790B2 (en) | 2026-01-20 |
| TW202313588A (zh) | 2023-04-01 |
| EP4347582A4 (en) | 2025-05-07 |
| IL308759A (en) | 2024-01-01 |
| CN117715905A (zh) | 2024-03-15 |
| JP2024520481A (ja) | 2024-05-24 |
| US20230026313A1 (en) | 2023-01-26 |
| CA3219348A1 (en) | 2022-12-01 |
| US11707462B2 (en) | 2023-07-25 |
| WO2022251502A1 (en) | 2022-12-01 |
| US20230310423A1 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014028A (es) | Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos. | |
| MX2024014500A (es) | Inhibidores piridinicos de la cinasa 1 de puntos de regulacion (chk1) y usos de estos | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| JOP20230190A1 (ar) | مركب كينازولين لتحفيز تحلل طافرة g12d لبروتين كيراس | |
| CO2026004964A2 (es) | Moduladores de kras | |
| GEAP202516803A (en) | Bicyclic amines as cdk2 inhibitors | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| BR112016008593A8 (pt) | composto, composição farmacêutica, método de regulação de transcrição gênica em uma célula, uso de um composto e método de inibição de reconhecimento mediado por bromodomínio de uma região de acetil lisina de uma proteína | |
| BRPI0511139A (pt) | compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente | |
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| CO2018013077A2 (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas | |
| MX384721B (es) | Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf. | |
| MX2022007441A (es) | Inhibidores de proteína tirosina fosfatasa y sus métodos de uso. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| CO2021000049A2 (es) | Inhibidores de ectonucleotidasa y métodos de uso de los mismos | |
| EP4512480A3 (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| BRPI0511350A (pt) | composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto | |
| BR112016028819A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos. | |
| NZ770260A (en) | Substituted heterocyclic inhibitors of ptpn11 | |
| CR20190361A (es) | Dendrímeros terapéuticos | |
| BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112021021826A2 (pt) | Terapias de combinação compreendendo os inibidores de apremilast e tyk2 | |
| BR112021019703A2 (pt) | Compostos heterocíclicos e usos dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: BOUNDLESS BIO, INC. (US) |